ESMO 2024: Treatment Breakthroughs in Pretreated Patients with Advanced or Metastatic NSCLC With or Without Actionable Genomic Alterations - Episode 5

Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC

, , , ,

This episode highlights the significance of third-generation EGFR TKIs in delaying subsequent therapies for resectable, stage IB to IIIA EGFR-mutated NSCLC, explores the risks of postresection treatments for disease progression, and discusses treatment considerations for patients across different stages, focusing on the ADAURA trial outcomes for stage IB to IIIA NSCLC.

Video content above is prompted by the following:

  • From a safety, tolerability, and quality-of-life perspective, how significant is the ability of a third-generation EGFR TKI to delay the requirement for subsequent therapy in patients with resectable, stage IB to IIIA, EGFR-mutated NSCLC?
  • What are some of the inherent postresection risks of later lines of treatment for EGFR-mutated NSCLC that has progressed despite standard of care?
  • What is your discussion in patients with stage IB vs IIIA disease?